Details for New Drug Application (NDA): 202970
✉ Email this page to a colleague
NDA 202970 describes LEVONORGESTREL AND ETHINYL ESTRADIOL, which is a drug marketed by Amneal Pharms, Glenmark Pharms Ltd, Lupin Ltd, Watson Labs, Xiromed, Barr, Dr Reddys Labs Sa, Hetero Labs, and Naari Pte Ltd, and is included in twenty-nine NDAs. It is available from nine suppliers. Additional details are available on the LEVONORGESTREL AND ETHINYL ESTRADIOL profile page.
The generic ingredient in LEVONORGESTREL AND ETHINYL ESTRADIOL is ethinyl estradiol; levonorgestrel. There are twenty-six drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; levonorgestrel profile page.
The generic ingredient in LEVONORGESTREL AND ETHINYL ESTRADIOL is ethinyl estradiol; levonorgestrel. There are twenty-six drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; levonorgestrel profile page.
Summary for 202970
| Tradename: | LEVONORGESTREL AND ETHINYL ESTRADIOL |
| Applicant: | Xiromed |
| Ingredient: | ethinyl estradiol; levonorgestrel |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL-28 | Strength | 0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG | ||||
| Approval Date: | Mar 23, 2018 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
